|
Eptifibatide
resources
|
|
|
|
|
|
DRUG INFO
Eptifibatide
Drug Name:
Eptifibatide
Indication: For treatment of myocardial infarction, acute coronary syndrome
Pharmacology: Not Available
Mechanism Of Action: Not Available
Drug Category: Anticoagulants; Antiplatelet Agents; unclassified therapeutic agents (92:00.00)
Brand Names/Synonyms: Integrilin; Integrilin (Millennium Pharm)
Dosage Forms: SOLUTION
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: N 6 -(aminoiminomethyl)-N 2 -(3-mercapto-1-oxopropyl-L-lysylglycyl-L-a-aspartyl-L-tryptophyl-L -prolyl-L-cysteinamide
Chemical Formula: C35H49N11O9S2
Half Life: ~2.5 hours
Drug Type: Approved Drug
# Accession No: BIOD00063
CAS Registry Number: 188627-80-7
|
|
|
|
|
|
Eptifibatide News
(When available)
It's Phase 3 for biotech CEO Dec 19, 2005
Bizjournals.com, ...(NYSE: SGP) for Integrilin, a cardiovascular drug the companies co-developed. Many of Millennium's 200 Integrilin sales and marketing ...
Millennium Details Strategic Drivers for Profitable Growth and ... Jan 5, 2006
PR Newswire (press release), ...over 2004 * Successful transition of the Company's leadership with a new president and CEO * Restructuring the collaboration for INTEGRILIN(R) (eptifibatide ...
Millennium Details Strategic Drivers for Profitable Growth and ... Jan 5, 2006
PharmaLive.com (press release), ...in manufacturing the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN; achieving revenue ...
Arginox Appoints Robert Terifay as President and Chief Operating ... Jan 6, 2006
Yahoo! News (press release) ...of the company's commercial presence in the acute care cardiovascular market, taking the company's first product, INTEGRILIN® (eptifibatide) Injection to ...
Arginox Appoints Robert Terifay as President and Chief Operating ... Jan 6, 2006
PR Newswire (press release), ...for establishment of the company's commercial presence in the acute care cardiovascular market, taking the company's first product, INTEGRILIN(R) (eptifibatide ...
Consistently High Complete and Overall Response Rates in Newly ... Dec 13, 2005
Yahoo! News (press release) ...the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN® (eptifibatide) Injection; achieving ...
|
|
|
